Development of an in vitro assay as correlate of passive immune protection against botulinum neurotoxin to minimize use of whole animal testing

Award Information
Agency:
Department of Defense
Amount:
$999,988.00
Program:
SBIR
Contract:
W81XWH-11-C-0085
Solitcitation Year:
2011
Solicitation Number:
2011.1
Branch:
Office for Chemical and Biological Defense
Award Year:
2012
Phase:
Phase II
Agency Tracking Number:
C2-0367
Solicitation Topic Code:
CBD11-109
Small Business Information
Electronic BioSciences INC
5754 Pacific Center Blvd Suite 204, San Diego, CA, -
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
129852864
Principal Investigator
 Eric Ervin
 Vice President of R&D
 (801) 582-0146
 ervin@electronicbio.com
Business Contact
 Tracey Wrightson
Title: Director of Operations
Phone: (858) 412-1800
Email: twrightson@electronicbio.com
Research Institution
 Stub
Abstract
This Small Business Innovation Research project will develop a non-animal based in vitro assay for determining the efficacy of Botulinum (BoNT) neutralizing therapeutics. New technologies are currently needed in order to facilitate the development and approval of BoNT vaccines and therapies and reduce the number of vertebrate animals used in medical testing. In Phase 1 of this project, the feasibility of the proposed system was demonstrated. During Phase 2, a complete working prototype will now be built, tested and validated against the standard mouse lethality neutralization (MLN) assay. Electronic BioSciences"proposed system will be capable of monitoring the complete neutralizing mechanism of therapies to all seven BoNT serotypes, making rapid, non-animal based neutralization efficacy testing possible.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government